文献速递毛发、甲与色素性疾病自身免疫性与大疱性皮肤病

乌帕替尼治疗斑秃的长期疗效与安全性:回顾性研究

Long-term efficacy and safety of upadacitinib in the treatment of alopecia areata: A retrospective study.
PubMed 文献 · J Am Acad Dermatol · 2026-07-31

该单中心回顾性研究纳入30例连续接受乌帕替尼治疗至少12个月的斑秃患者,评估长期疗效与安全性。第12个月时SALT50、SALT75、SALT90应答率分别为90.0%、80.0%、56.67%,且随时间呈上升趋势;有特应性背景者早期改善更优,全程未报告严重不良事件。

要点

  • 乌帕替尼治疗斑秃第12个月SALT50应答率达90.0%
  • 有特应性背景者在治疗早期更易达到疗效目标
  • 研究期间未报告严重不良事件

核心结论

  • 真实世界中长期使用乌帕替尼治疗斑秃具有显著疗效和良好安全性。
  • 有特应性背景的患者在早期更可能达到疗效目标。

研究设计与样本

  • 单中心回顾性研究,纳入30例连续接受乌帕替尼治疗至少12个月的斑秃患者。
  • 患者中女性占73.33%,有特应性背景者占36.67%,包括7名儿童、6名青少年和17名成人。
  • 在基线和每3个月评估疾病严重程度,并系统记录治疗期间发生的不良事件。

主要发现

  • 第12个月时SALT50、SALT75、SALT90应答率分别为90.0%、80.0%、56.67%,且随时间呈上升趋势。
  • 有特应性背景的患者在治疗早期SALT评分改善优于无特应性背景者。
  • 整个研究期间未报告严重不良事件。

关键数值与推荐

  • 主要终点为第12个月SALT50、SALT75、SALT90应答率,分别为90.0%、80.0%、56.67%。

临床怎么用

  • 真实世界中乌帕替尼可用于斑秃的长期治疗,尤其对有特应性背景者早期疗效更佳。
  • 治疗期间需定期评估SALT评分以监测疗效随时间的变化。

局限性

  • 单中心回顾性研究,样本量相对较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term efficacy and safety of upadacitinib for alopecia areata is unknown in real-world practice. OBJECTIVE: To evaluate long-term efficacy and safety of upadacitinib in a real-world setting and to explore the predictive factors that may influence the treatment response. METHODS: A retrospective study was conducted on 30 patients continuously taking upadacitinib for at least 12 months. The disease severity was evaluated at baseline and every 3 months. Adverse events occurred during treatment were systematically recorded. RESULTS: A total of 30 patients were included (73.33% female; 36.67% with atopic background; 7 children, 6 adolescents and 17 adult). The primary end points were the Severity of Alopecia Tool50, Severity of Alopecia Tool75, and Severity of Alopecia Tool90 response rates at months 12, which were 90.0%, 80.0%, and 56.67%, respectively, and showed an upward trend over time. The Severity of Alopecia Tool score improvement of patients with atopic background was better than those without atopic background in the early stage of treatment. No serious adverse events were reported throughout the study period. LIMITATIONS: Single-center, retrospective study and relatively small sample size. CONCLUSION: Long-term treatment of alopecia areata with upadacitinib has significant efficacy and favorable safety in real-world setting. Patients with atopic background are more likely to achieve the efficacy target in the early stage.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wang H, Li X, Sun Y, et al. Long-term efficacy and safety of upadacitinib in the treatment of alopecia areata: A retrospective study. J Am Acad Dermatol. 2026. PMID: 42537850. doi:10.1016/j.jaad.2026.07.098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。